Journal Information
Vol. 42. Issue 6.
Pages 283-289 (June 2006)
Share
Share
Download PDF
More article options
Vol. 42. Issue 6.
Pages 283-289 (June 2006)
Original Articles
Full text access
Evaluation of Clinical Practice in Patients Admitted With Community-Acquired Pneumonia Over a 4-Year Period
Visits
4836
Alberto Capelasteguia,
Corresponding author
acapelas@hgda.osakidetza.net

Correspondence: Dr. A. Capelastegui. Servicio de Neumología. Hospital de Galdakao. Barrio Labeaga, s/n. 48960 Galdakao. Vizcaya. España
, Pedro P. Españaa, José M. Quintanab, Inmaculada Gorordoa, Celia Sañudoc, Amaia Bilbaod
a Servicio de Neumología, Hospital de Galdakao, Galdakao, Vizcaya, Spain
b Unidad de Investigación, Hospital de Galdakao, Galdakao, Vizcaya, Spain
c Servicio de Urgencias, Hospital de Galdakao, Galdakao, Vizcaya, Spain
d Fundación Vasca de Innovación e Investigación Sanitarias (BIOEF), Vizcaya, Spain
This item has received
Article information
Objective

Since March 2000 we have been using a clinical practice guideline in the management of patients diagnosed with community-acquired pneumonia (CAP). The objective of this study was to analyze the evolution of quality of care received by these patients.

Patients and methods

This was a prospective observational study comparing the process of care and outcomes of 4 consecutive 1-year periods (March 1, 2000 through February 29,2004) in all patients admitted for CAP.

Results

Over the 4 years studied, the following statistically significant trends were observed: reductions in hospital admissions (P<.001), length of hospital stay (P«.05), and total duration of antibiotic treatment (P«.05); and increases in the coverage of atypical pathogens (P«.001) and administration of antibiotics within 8 hours of hospital arrival (P«.001). No significant differences were found in readmissions within 30 days, or in-hospital and 30-day mortality. Two other areas of improvement were also identified: a low percentage of admissions to the intensive care unit (4.4%) and of unnecessary hospitalization of low-risk patients (36.8%).

Conclusions

Systematic monitoring of the indicators of our clinical guidelines provided us with information about our clinical practice and facilitated an evaluation of the same. Many of these indicators were found to have evolved favorably and areas of improvement were identified.

Key words:
Community-acquired pneumonia
Clinical guidelines
Quality indicators
Objetivo

En nuestro hospital utilizamos desde marzo de 2000 una guía clínica para el tratamiento de los pacientes diagnosticados de neumonía adquirida en la comunidad (NAC). El objetivo de este estudio ha sido analizar la evolución de la calidad del tratamiento facilitado a los pacientes ingresados por NAC.

Pacientes y métodos

Se ha realizado un estudio observacional prospectivo. Se compararon, en 4 períodos consecutivos de 1 año (1 de marzo de 2000 a 29 de febrero de 2004), el tratamiento y los resultados de todos los pacientes ingresados por NAC.

Resultados

A lo largo de los 4 años se demostraron tendencias estadísticamente significativas en los siguientes indicadores: reducción de los ingresos hospitalarios (p < 0,001), de la duración de la estancia hospitalaria (p < 0,05) y de la duración total del tratamiento antibiótico (p < 0,05); aumento de la cobertura de gérmenes atípicos (p < 0,001) y de la administración del antibiótico en las primeras 8 h (p < 0,001). No se observaron diferencias significativas en la mortalidad intrahospitalaria, en la mortalidad en 30 días y en los reingresos en 30 días. También se identificaron 2 áreas de mejora: el bajo porcentaje de ingresos en la unidad de cuidados intensivos (4,4%) y los ingresos injustificados entre los pacientes de riesgo bajo (36,8%).

Conclusiones

El control sistemático de los indicadores de nuestra guía clínica nos permitió conocer y evaluar nuestra práctica clínica. Se comprobó una evolución favorable de muchos de estos indicadores y se identificaron áreas de mejora.

Palabras clave:
Neumonía adquirida en la comunidad
Guías clínicas
Indicadores de calidad
Full text is only aviable in PDF
REFERENCES
[1]
J Almirall, I Bolíbar, J Vidal, G Sauca, P Coll, B Niklasson, et al.
Epidemiology of community-acquired pneumonia in adults: a population-based study.
Eur Respir J, 15 (2000), pp. 757-763
[2]
JF Guest, A Morris.
Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
Eur Respir J, 10 (1997), pp. 1530-1534
[3]
BG Feagan, TJ Marrie, CY Lau, SL Wheeler, CJ Wong, MK Vandervoort.
Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.
Can Med Assoc J, 162 (2000), pp. 1415-1420
[4]
D McCormick, MJ Fine, CM Coley, TJ Marrie, JR Lave, DS Obrosky, et al.
Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?.
Am J Med, 107 (1999), pp. 5-12
[5]
A Ortqvist.
Antibiotic treatment of community-acquired pneumonia in clinical practice: a European survey.
J Antimicrob Chemother, 35 (1995), pp. 205-212
[6]
D Nathwani, E Rubinstein, G Barlow, P Davey.
Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?.
Clin Infect Dis, 32 (2001), pp. 728-741
[7]
DC Rhew, MB Goetz, PG Shekelle.
Evaluating quality indicators for patients with community-acquired pneumonia.
J Qual Improv, 27 (2001), pp. 575-590
[8]
NC Dean, MP Silver, KA Bateman, B James, CJ Hadlock, D Hate.
Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia.
Am J Med, 110 (2001), pp. 451-457
[9]
TJ Marrie, CY Lau, SI Wheeler, CJ Wong, MK Vandervoort, BG Feagan, for the CAPITAL Study Investigators.
A controlled trial of a critical pathway for treatment of community-acquired pneumonia.
JAMA, 283 (2000), pp. 749-755
[10]
A Capelastegui, PP España, JM Quintana, I Gorordo, M Ortega, I Idoiaga, et al.
Improvement of process-of-care and outcomes after implementing a guideline for management of community-acquired pneumonia: a controlled before-and-after study.
Clin Infect Dis, 39 (2004), pp. 955-963
[11]
MJ Fine, TE Auble, DM Yealy, BH Hanusa, LA Weissfeld, DE Singer, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med, 336 (1997), pp. 243-250
[12]
PP España, A Capelastegui, JM Quintana, A Soto, I Gorordo, M Garcia Urbaneja, et al.
A prediction rule to identify allocation of inpatient care in community-acquired pneumonia.
Eur Respir J, 21 (2003), pp. 695-701
[13]
J Frias, M Gomis, J Prieto, J Mensa, E Bouza, JA García-Rodríguez, et al.
Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad.
Rev Esp Quimioter, 11 (1998), pp. 255-261
[14]
S Ewig, M Ruiz, J Mensa, MA Marcos, JA Martínez, F Arancibia, et al.
Severe community-acquired pneumonia: assessment of severity criteria.
Am J Respir Crit Care Med, 158 (1998), pp. 1102-1108
[15]
A Agresti.
Categorical data analysis, John Wiley and Sons, (1990),
[16]
I Aguirre, JJ Bilbao, M Olarreaga, M Narzabal, JR Aguinaga, I Ventura, et al.
Neumonías adquiridas en la comunidad de Andoain.
Aten Primaria, 12 (1993), pp. 359-362
[17]
C Mirete Ferrer, F Gutiérrez Rodero, JC Rodríguez Díaz, G Royo Garcia, C Shum Fhunk, A Martín Hidalgo.
Etiología de la neumonía adquirida en la comunidad tratada ambulatoriamente. Utilidad de un protocolo diagnóstico con pruebas microbiológicas convencionales y detección de antígenos de Streptococcus pneumoniae y Legionella pneumophila en orina.
Med Clin (Barc), 117 (2001), pp. 657-659
[18]
MA Woohead, JT McFarlane, JS McCracken, DH Rose, RG Finch.
Prospective study of the aetiology and outcome of pneumonia in the community.
Lancet, 2 (1987), pp. 671-674
[19]
HM Foy, MK Cooney, R Mcmahan, JT Grayston.
Viral and Mycoplasma pneumonia in a prepaid medical care group during an eight-year period.
Am J Epidemiol, 97 (1973), pp. 93-102
[20]
MF Minogue, CM Coley, MJ Fine, TJ Marrie, WN Kapoor, DE Singer.
Patients hospitalized after initial outpatient treatment for community acquired pneumonia.
Ann Emerg Med, 31 (1998), pp. 376-380
[21]
C Jokinen, L Heiskanen, H Juvonen, S Kallinen, K Karkola, M Korppi, et al.
Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland.
Am J Epidemiol, 137 (1993), pp. 977-988
[22]
MJ Fine, HM Pratt, DS Obrosky, JR Lave, LJ Mcintosh, DE Singer, et al.
Relation between length of hospital stay and cost of care for patients with community-acquired pneumonia.
Am J Med, 109 (2000), pp. 434-436
[23]
R Fernández Álvarez, JA Gullón Blanco, G Rubinos Cuadrado, A Jímenez Sosa, C Hernández García, A Medina Gonzálvez, et al.
Neumonía adquirida en la comunidad: influencia de la duración de la antibioterapia intravenosa en la estancia hospitalaria y relación coste/efectividad.
Arch Bronconeumol, 37 (2001), pp. 366-370
[24]
EA Halm, MJ Fine, WN Kapoor, DE Singer, TJ Marrie, AL Siu.
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia.
Arch Intern Med, 162 (2002), pp. 1278-1284
[25]
JA Ramírez, S Vargas, GW Ritter, ME Brier, A Wright, S Smith, et al.
Early switch from intravenous to oral antibiotics and early discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.
Arch Intern Med, 159 (1999), pp. 2449-2454
[26]
DC Rhew, D Hackner, L Henderson, AG Ellrodt, SR Weingarten.
The clinical benefit of in-hospital observation in "low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
Chest, 113 (1998), pp. 142-146
[27]
TP Meehan, MJ Fine, HM Krumholz, JD Scinto, DH Galusha, JT Mockalis, et al.
Quality of care, process, and outcomes in elderly patients with pneumonia.
JAMA, 278 (1997), pp. 2080-2084
[28]
DS Battleman, M Callahan, TT Howard.
Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia.
Arch Intern Med, 162 (2002), pp. 682-688
[29]
LJ Eron, S Passos.
Early discharge of infected patients through appropriate antibiotic use.
Arch Intern Med, 161 (2001), pp. 61-65
[30]
D Nathwani, F Williams, J Winter, S Ogston, P Davey.
Use of indicators to evaluate the quality of community-acquired pneumonia management.
Clin Infect Dis, 34 (2002), pp. 318-323
[31]
WS Lim, MM van der Eerden, R Laing, WG Boersma, N Karalus, GI Town, et al.
Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
Thorax, 58 (2003), pp. 377-382
[32]
S Ewig, H Schäfer, A Torres.
Severity assessment in community-acquired pneumonia.
Eur Respir J, 16 (2000), pp. 1193-1201
[33]
O Leroy, P Devos, B Guery, H Georges, C Vandenbussche, C Coffinier, et al.
Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs.
Chest, 116 (1999), pp. 157-165
[34]
ES Holmboe, TP Meehan, MJ Radford, Y Wang, TA Marciniak, HM Krumholz.
Use of critical pathways to improve the care of patients with acute myocardial infarction.
Am J Med, 107 (1999), pp. 324-331
[35]
SD Pearson, SF Kleefield, JR Soukop, EF Cook, TH Lee.
Critical pathways intervention to reduce length of hospital stay.
Am J Med, 110 (2001), pp. 175-180
[36]
LA Chu, DW Bratzler, RJ Lewis, C Murray, L Moore, C Shook, et al.
Improving the quality of care for patients with pneumonia in a very small hospital.
Arch Intern Med, 163 (2003), pp. 326-332
[37]
A Capelastegui, PP España, JM Quintana, I Gorordo, MS Gallardo, I Idoiaga, et al.
Management of community-acquired pneumonia and secular trends at different hospitals.
Respir Med, 99 (2005), pp. 268-278
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?